We’re BACK! Join us IN-PERSON.
AAPS PharmSci 360
Visit booth #1219 to:
- Enhance your product knowledge with ADMET Predictor®, DILIsym®, GastroPlus®, MonolixSuite™, and more
- Discuss your PBBM, PBPK, Population PK & Exposure Response modeling project needs
- Schedule a personalized software training course for you, your team, or the entire organization
Establishment of preclinical mechanistic in vitro-in vivo correlations for long-acting injectable suspensions
Poster #: M1030-02-07 | Presented by: Daniela Silva
The purpose of this study was to use different modeling approaches to mechanistically understand the in vivo performance of different long-acting injectable suspensions (reference listed drug of medroxyprogesterone acetate and formulation variants) in preclinical species and to establish an in vitro – in vivo correlation.
Date/Time: Monday, October 17th at 10:30 am EST, Forum # 2, Monitor #07.
ILDsym successfully simulates SSc-ILD pathophysiology and inter-patient variability
Poster #: M1330-11-62 | Presented by: Zackary Kenz
This work aimed to develop a mechanistic QSP model for systemic sclerosis (SSc)-associated interstitial lung disease (ILD) pathophysiology validated with clinical data and capable of representing responses to existing and novel treatments.
Date/Time: Monday, October 17th at 1:30 pm EST, Forum #11, Monitor #62.
Use of Quantitative Systems Toxicology (QST) to Identify Potential Intrinsic Mechanisms of Toxicity
Poster #: M1530-11-64 | Presented by: Christina Battista
This study aimed to investigate whether a QST model could account for liver chemistry abnormalities observed during BAY1128688 treatment and provide insight into mechanisms driving hepatotoxicity and bilirubin elevations.
Date: Monday, October 17th at 3:30 pm EST, Forum #11, Monitor #64.
Physiologically Based Pharmacokinetic (PBPK) Modeling of Rifampicin and Its Application for Drug-Drug Interaction with Midazolam in Adults
Poster #: W0930-05-26 | Presented by: Suvarchala Avvari
The purpose was to develop a mechanistic PBPK model for RIF which accounts for all the relevant mechanisms after IV and PO administration in healthy and tuberculosis (TB) subjects. This model was validated by predicting the effect of RIF administration on midazolam (MDZ) PK.
Date/Time: Wednesday, October 19th at 9:30 am EST, Forum #5, Monitor#26.
Clinical Ocular Exposure Extrapolation Using PBPK Modeling and Simulation: Gatifloxacin Solution Case Study
Poster #: W1230-02-1 | Presented by: Scientist II, Farah Al Qaraghuli
Development and validation of gatifloxacin administration as an ophthalmic solution in rabbits as well as predicting its clinical exposure in humans.
Date/Time: Wednesday, October 19th at 12:30 pm EST, Forum #02,
Save-the-Date: October 18th for the 18th Annual SLP Forum
(more information coming soon)
Don’t forget to stop by and see us in Booth #1219.
We look forward to seeing you there!
Copyright © 2022 Simulations Plus, All rights reserved.
Simulations Plus, Inc. Corporate Headquarters
42505 10th Street West
Lancaster, CA 93534
Cognigen, a Simulations Plus division
500 Seneca Street, Suite 600
Buffalo, NY 14204
DILIsym Services, a Simulations Plus division
Six Davis Drive
PO Box 12317
Research Triangle Park, NC 27709
Lixoft, a Simulations Plus division
8 rue de la Renaissance Batiment D
92160 Antony, France
Telephone: +33 9 72 53 91 80